ArticleBMJ open2024

HIV-1 subtype-specific drug resistance on dolutegravir-based antiretroviral therapy: protocol for a multicentre study (DTG RESIST).

Matthias Egger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.